Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28643625 | 0.97 | FDPS (0.30) | FDPSBLMTDP1 | |
| SCHEMBL29057342 | 0.80 | — | — | |
| SCHEMBL27541430 | 0.80 | CA2 (0.32) | CA2 | |
| SCHEMBL28435210 | 0.80 | CA1 (0.33) | CA1CA2CA7CA13 | |
| SCHEMBL29279657 | 0.75 | — | — | |
| SCHEMBL28858846 | 0.74 | CA1 (0.36) | CA1CA2CA7CA13 | |
| SCHEMBL27750279 | 0.73 | CA2 (0.44) | CA1CA2 | |
| SCHEMBL1493042 | 0.72 | — | — | |
| Lithium Ion SCHEMBL31557359 | 0.72 | — | — | |
| SCHEMBL28668147 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003035669-A1 | AMPHIPHILIC CATIONIC LIPIDS DERIVED FROM CHOLESTEROL | STERRENBELD BIOTECHNOLOGIE NORTH AMERICA, INC. (US) | 2003-05-01 | — | — | WO | claimed |
| WO-2024114190-A1 | ELECTROLYTE COMPOSITION, METHOD FOR SECONDARY ELECTROLYTE FILLING, AND LITHIUM SECONDARY BATTERY | 九江天赐高新材料有限公司 | 2024-06-06 | — | — | WO | disclosed |
| CN-111303088-B | Synthetic method of difurane compound | 南京工业大学 | 2022-10-14 | — | — | CN | disclosed |
| CN-114958295-A | Ultralow-adhesive-force and low-climbing organic silicon pressure-sensitive adhesive as well as preparation method and application thereof | 江苏至昕新材料有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114854367-A | Anti-fingerprint glass organic silicon pressure-sensitive adhesive and preparation method and application thereof | 江苏至昕新材料有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-102532378-A | Catalyst composition for preparing 1,2-polybutadiene, and preparation method for 1,2-polybutadiene | CHANGCHUN APPLIED CHEMISTRY | 2012-07-04 | — | — | CN | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | CANNIZZARO CARINA | 2009-09-10 | — | — | US | disclosed |
| US-7470724-B2 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1620110-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| CN-1649885-A | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2005-08-03 | — | — | CN | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004096236-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-5344974-A | Process for the preparation of N-acyl derivatives of 5-aminolevulinic acid, as well as the hydrochloride of the free acid | SUDZUCKER AKTIENGESELLSCHAFT MANNHEIM/OCHENSFURT (DE) | 1994-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | PHOSPHO1, NFATC1, IFNG | FDPS 363/4885BLM 2871/4885TDP1 2777/4885 |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | FDPS 504/4885BLM 4243/4885TDP1 554/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | FDPS 330/4885BLM 4340/4885TDP1 1526/4885 |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | FDPS 228/4885BLM 3629/4885TDP1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.